Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Exploratory ad hoc analyses from SPOTLIGHT and GLOW trials report quantitative differences in median progression-free survival (mPFS) and median overall survival (mOS) for patients treated with...
Babs is sharing her family’s history with progressive retinal disease GA, the advanced form of dry age-related macular degeneration (AMD), is a serious condition that may lead to irreversible...
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with...
XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical...
Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy...
Follow U.S. news
